IBS announces global commitment to pharmaceutical industry

Andre Grigjanis appointed VP IBS Pharma

IBS has named Pharmaceuticals as part of its strategy to focus on key global industries. Andre Grigjanis was appointed as Vice President IBS Pharma to manage IBS’ worldwide activities for this industry. This includes marketing and sales coordination, training of IBS sales and consultancy, working with national and international Pharma associations and business partners.

on 4 April 2007

The new Release 6 of IBS Pharma Industry Product is now available. IBS Pharma 6 is a total solution for large and midsized pharmaceutical companies. The new release is based on the latest release of IBS Enterprise 6 ERP-software and consists of many new functions specifically designed to increase the efficiency, productivity and profitability of pharmaceutical wholesalers.

Andre Grigjanis comments, “IBS already has an unrivalled reputation for delivering solutions to the global pharmaceutical industry, with installations at many of world’s leading wholesale and distribution companies, such as Galexis, Alloga, Sigma, Audifar, Itriafarma and Marzam. We now have a powerful and highly functional software solution that has been developed based on the demands of real pharmaceutical companies. This is coupled with our dedicated industry knowledge and experience that ensures successful implementation and on-going operation of a complete ERP for our pharmaceutical customers throughout the world.”

IBS Pharma 6 is the most advanced complete business software solution for pharmaceutical distributors and wholesalers. The new version incorporates key functionality that customers have requested as being essential for the industry, such as electronic order reception and confirmation, pick split and pick consolidation, scanning throughout warehouse processes, batch control, online connection to conveyor systems and picking robots, automatic purchasing processes, spot market communications, alternative items and Generics handling.

Andre Grigjanis concludes, “A key part of our global strategy for the pharmaceuticals industry is to ensure we are continually working on the important challenges for the market. These include the threats posed from counterfeiting and the need for effective track and trace and labelling capabilities. The significant investment IBS makes in research and development capabilities means that we can continually develop new technology and solutions for key industry issues. Our new approach to the pharmaceutical industry means that we can be much more focused and responsive to the needs and influences of the market.”

About IBS

IBS AB (XSSE: IBS B), International Business Systems, is a leading provider of business software for supply chain management, business intelligence, financial control, and demand-driven manufacturing. IBS’ primary focus is mid-sized and large wholesale distributors as well as sales and manufacturing companies in international groups, especially in pharmaceuticals, electrical and electronic parts and equipment, paper and packaging, automotive parts and supplies, machinery, industrial supplies food & beverage and consumer durables.